Tocilizumab

Identification

Name
Tocilizumab
Accession Number
DB06273
Type
Biotech
Groups
Approved
Biologic Classification
Protein Based Therapies
Monoclonal antibody (mAb)
Description

Tocilizumab is a recombinant, humanized, anti-human interleukin 6 (IL-6) receptor monoclonal antibody that achieves a significant therapeutic response rate. The light chain is made up of 214 amino acids. The heavy chain is made up of 448 amino acids. The four polypeptide chains are linked intra- and inter-molecularly by disulfide bonds. FDA approved on January 8, 2010.

Tocilizumab (injection) was further approved by the FDA for the treatment of adults with giant cell arteritis, an inflammation of the blood vessels (vasculitis) in May, 2017. In a double-blind, placebo-controlled study, the patients achieved sustained remission from Week 12 through Week 52, which was associated with significant improvements in symptoms of giant cell arteritis, normalization of inflammatory laboratory tests and tapering the use of corticosteroids [2].

Protein structure
Db06273
Protein chemical formula
C6428H9976N1720O2018S42
Protein average weight
148000.0 Da
Sequences
Not Available
Synonyms
  • Atlizumab
External IDs
MRA / R-1569 / RHPM-1 / RO-4877533
Prescription Products
NameDosageStrengthRouteLabellerMarketing StartMarketing End
ActemraSolution80 mgIntravenousHoffmann La Roche2010-05-26Not applicableCanada
ActemraInjection, solution, concentrate20 mg/mLIntravenousGenentech, Inc.2010-01-08Not applicableUs
ActemraSolution400 mgIntravenousHoffmann La Roche2010-05-26Not applicableCanada
ActemraInjection, solution180 mg/mLSubcutaneousGenentech, Inc.2013-10-21Not applicableUs
ActemraInjection, solution, concentrate20 mg/mLIntravenousGenentech, Inc.2010-01-08Not applicableUs
ActemraSolution200 mgIntravenousHoffmann La Roche2010-05-26Not applicableCanada
ActemraInjection, solution, concentrate20 mg/mLIntravenousGenentech, Inc.2010-01-08Not applicableUs
ActemraSolution162 mgSubcutaneousHoffmann La Roche2014-05-30Not applicableCanada
International/Other Brands
RoActemra
Categories
UNII
I031V2H011
CAS number
375823-41-9

Pharmacology

Indication

Indicated for the treatment of adult patients with moderately to severely active rheumatoid arthritis (RA) who have had an inadequate response to one or more Disease-Modifying Anti-Rheumatic Drugs (DMARDs). It is also indicated for the treatment of active polyarticular juvenile idiopathic arthritis (PJIA) and active systemic juvenile idiopathic arthritis (SJIA) in patients 2 years of age and older.

Associated Conditions
Pharmacodynamics

A decrease in C-reactive protein (CRP) was noted as early as week 2. Changes in pharmacodynamic parameters were observed (i.e., decreases in rheumatoid factor, erythrocyte sedimentation rate (ESR), serum amyloid A and increases in hemoglobin) with both doses, however the greatest improvements were observed with 8 mg per kg tocilizumab. Similar pharmacodynamic changes were also observed in active polyarticular juvenile idiopathic arthritis and active systemic juvenile idiopathic arthritis patients.

Mechanism of action

Interleukin (IL)-6 plays essential roles not only in the immune response, but also in haematopoiesis and the central nervous system. Unregulated production of IL-6 has been found in chronic inflammatory autoimmune diseases, such as rheumatoid arthritis (RA), systemic onset juvenile idiopathic arthritis (soJIA), Crohn's disease (CD), systemic lupus erythematosus (SLE) and vasculitis. Furthermore, IL-6 activities can explain many symptoms of these diseases. More importantly, serum levels of IL-6 are correlated with disease activity. Tocilizumab binds specifically to both soluble and membrane-bound IL-6 receptors (sIL-6R and mIL-6R), and has been shown to inhibit IL-6-mediated signaling through these receptors.

TargetActionsOrganism
AInterleukin-6 receptor subunit alpha
antibody
Human
Absorption

When 4 mg/kg of tocilizumab was given every 4 weeks to RA patients, the pharmacokinetic parameters at steady state are as follows: AUC = 13000 ± 5800 mcg∙h/mL; Cmax = 88.3 ± 41.4 mcg/mL. Tocilizumab accumulates following repeated doses. Furthermore, an increased body weight may increase plasma levels of tocilizumab.

When a dose of 8 mg/kg of tocilizumab is given to PJIA patients, the pharmacokinetic parameters are as follows: AUC = 29500 ± 8660 mcg∙h/mL; Cmax = 182 ± 37 mcg/mL.

When a dose of 8 mg/kg of tocilizumab is given to SJIA patients, the pharmacokinetic parameters are as follows: AUC = 32200 ± 9960 mcg∙h/mL; Cmax = 245 ± 57.2 mcg/mL.

Volume of distribution

In rheumatoid arthritis patients the central volume of distribution was 3.5 L and the peripheral volume of distribution was 2.9 L, resulting in a volume of distribution at steady state of 6.4 L.

In pediatric patients with PJIA, the central volume of distribution was 1.98 L, the peripheral volume of distribution was 2.1 L, resulting in a volume of distribution at steady state of 4.08 L.

In pediatric patients with SJIA, the central volume of distribution was 0.94 L, the peripheral volume of distribution was 1.60 L resulting in a volume of distribution at steady state of 2.54 L.

Protein binding
Not Available
Metabolism
Not Available
Route of elimination

Following intravenous dosing, tocilizumab undergoes biphasic elimination from the circulation.

Half life

The half-life of tocilizumab is concentration-dependent. The concentration-dependent apparent half-life is up to 11 days for 4 mg/kg and up to 13 days for 8 mg/kg every 4 weeks in patients with RA at steady-state. The half-life in children with PJIA is up to 16 days. The half-life in pediatric patients with SJIA is up to 23 days.

Clearance

The clearance of tocilizumab decreases with increasing dose. At the 10 mg/kg single dose in RA patients, mean clearance was 0.29 ± 0.10 mL/hr/kg. The total clearance of tocilizumab is concentration-dependent and is the sum of the linear clearance and the nonlinear clearance. At low concentrations, concentration-dependent nonlinear clearance is dominant. At high concentrations, linear clearance dominates. The estimated linear clearances for specific patient populations are as follows: RA = 12.5 mL/h; PJIA, pediatric patients = 5.8 mL/h; SJIA, pediatric patients = 7.1 mL/h.

Toxicity

Most common adverse reactions (incidence of at least 5%): upper respiratory tract infections, nasopharyngitis, headache, hypertension, increased ALT.

Affected organisms
  • Humans and other mammals
Pathways
Not Available
Pharmacogenomic Effects/ADRs
Not Available

Interactions

Drug Interactions
DrugInteractionDrug group
AbataceptThe risk or severity of adverse effects can be increased when Tocilizumab is combined with Abatacept.Approved
AbemaciclibThe serum concentration of Abemaciclib can be decreased when it is combined with Tocilizumab.Approved, Investigational
AbirateroneThe serum concentration of Abiraterone can be decreased when it is combined with Tocilizumab.Approved
AcenocoumarolThe serum concentration of Acenocoumarol can be decreased when it is combined with Tocilizumab.Approved, Investigational
AcetaminophenThe serum concentration of Acetaminophen can be decreased when it is combined with Tocilizumab.Approved
AdalimumabTocilizumab may increase the immunosuppressive activities of Adalimumab.Approved
AdinazolamThe serum concentration of Adinazolam can be decreased when it is combined with Tocilizumab.Approved
AfelimomabTocilizumab may increase the immunosuppressive activities of Afelimomab.Investigational
AlbendazoleThe serum concentration of Albendazole can be decreased when it is combined with Tocilizumab.Approved, Vet Approved
AlclometasoneThe serum concentration of Alclometasone can be decreased when it is combined with Tocilizumab.Approved
AlfentanilThe serum concentration of Alfentanil can be decreased when it is combined with Tocilizumab.Approved, Illicit
AlfuzosinThe serum concentration of Alfuzosin can be decreased when it is combined with Tocilizumab.Approved, Investigational
AliskirenThe serum concentration of Aliskiren can be decreased when it is combined with Tocilizumab.Approved, Investigational
AllylestrenolThe serum concentration of Allylestrenol can be decreased when it is combined with Tocilizumab.Approved
AlmotriptanThe serum concentration of Almotriptan can be decreased when it is combined with Tocilizumab.Approved, Investigational
AlogliptinThe serum concentration of Alogliptin can be decreased when it is combined with Tocilizumab.Approved
AlosetronThe serum concentration of Alosetron can be decreased when it is combined with Tocilizumab.Approved, Withdrawn
alpha-Tocopherol acetateThe serum concentration of alpha-Tocopherol acetate can be decreased when it is combined with Tocilizumab.Approved
AlprazolamThe serum concentration of Alprazolam can be decreased when it is combined with Tocilizumab.Approved, Illicit, Investigational
AmbrisentanThe serum concentration of Ambrisentan can be decreased when it is combined with Tocilizumab.Approved, Investigational
AmbroxolThe serum concentration of Ambroxol can be decreased when it is combined with Tocilizumab.Approved, Investigational
AminophenazoneThe serum concentration of Aminophenazone can be decreased when it is combined with Tocilizumab.Approved, Withdrawn
AminophyllineThe serum concentration of Aminophylline can be decreased when it is combined with Tocilizumab.Approved
AmiodaroneThe serum concentration of Amiodarone can be decreased when it is combined with Tocilizumab.Approved, Investigational
AmitriptylineThe serum concentration of Amitriptyline can be decreased when it is combined with Tocilizumab.Approved
AmlodipineThe serum concentration of Amlodipine can be decreased when it is combined with Tocilizumab.Approved
AmprenavirThe serum concentration of Amprenavir can be decreased when it is combined with Tocilizumab.Approved, Investigational
AnakinraThe risk or severity of adverse effects can be increased when Anakinra is combined with Tocilizumab.Approved
Anthrax immune globulin humanThe risk or severity of adverse effects can be increased when Tocilizumab is combined with Anthrax immune globulin human.Approved
AntipyrineThe serum concentration of Antipyrine can be decreased when it is combined with Tocilizumab.Approved, Investigational
ApalutamideThe serum concentration of Apalutamide can be decreased when it is combined with Tocilizumab.Approved, Investigational
ApixabanThe serum concentration of Apixaban can be decreased when it is combined with Tocilizumab.Approved
ApremilastThe serum concentration of Apremilast can be decreased when it is combined with Tocilizumab.Approved, Investigational
AprepitantThe serum concentration of Aprepitant can be decreased when it is combined with Tocilizumab.Approved, Investigational
ArgatrobanThe serum concentration of Argatroban can be decreased when it is combined with Tocilizumab.Approved, Investigational
AripiprazoleThe serum concentration of Aripiprazole can be decreased when it is combined with Tocilizumab.Approved, Investigational
ArtemetherThe serum concentration of Artemether can be decreased when it is combined with Tocilizumab.Approved
AsenapineThe serum concentration of Asenapine can be decreased when it is combined with Tocilizumab.Approved
AstemizoleThe serum concentration of Astemizole can be decreased when it is combined with Tocilizumab.Approved, Withdrawn
AsunaprevirThe serum concentration of Asunaprevir can be decreased when it is combined with Tocilizumab.Approved, Investigational, Withdrawn
AtazanavirThe serum concentration of Atazanavir can be decreased when it is combined with Tocilizumab.Approved, Investigational
AtorvastatinThe serum concentration of Atorvastatin can be decreased when it is combined with Tocilizumab.Approved
AvanafilThe serum concentration of Avanafil can be decreased when it is combined with Tocilizumab.Approved
AvatrombopagThe serum concentration of Avatrombopag can be decreased when it is combined with Tocilizumab.Approved, Investigational
AxitinibThe serum concentration of Axitinib can be decreased when it is combined with Tocilizumab.Approved, Investigational
AzelastineThe serum concentration of Azelastine can be decreased when it is combined with Tocilizumab.Approved
AzithromycinThe serum concentration of Azithromycin can be decreased when it is combined with Tocilizumab.Approved
Bacillus calmette-guerin substrain connaught live antigenThe risk or severity of adverse effects can be increased when Tocilizumab is combined with Bacillus calmette-guerin substrain connaught live antigen.Approved, Investigational
Bacillus calmette-guerin substrain tice live antigenThe risk or severity of adverse effects can be increased when Tocilizumab is combined with Bacillus calmette-guerin substrain tice live antigen.Approved
BanoxantroneThe serum concentration of Banoxantrone can be decreased when it is combined with Tocilizumab.Investigational
BaricitinibThe serum concentration of Baricitinib can be decreased when it is combined with Tocilizumab.Approved, Investigational
BCG vaccineThe therapeutic efficacy of BCG vaccine can be decreased when used in combination with Tocilizumab.Investigational
BedaquilineThe serum concentration of Bedaquiline can be decreased when it is combined with Tocilizumab.Approved
BelimumabThe risk or severity of adverse effects can be increased when Tocilizumab is combined with Belimumab.Approved
BenidipineThe serum concentration of Benidipine can be decreased when it is combined with Tocilizumab.Approved, Investigational
BenzphetamineThe serum concentration of Benzphetamine can be decreased when it is combined with Tocilizumab.Approved, Illicit
Benzyl alcoholThe serum concentration of Benzyl alcohol can be decreased when it is combined with Tocilizumab.Approved
BexaroteneThe serum concentration of Bexarotene can be decreased when it is combined with Tocilizumab.Approved, Investigational
BezafibrateThe serum concentration of Bezafibrate can be decreased when it is combined with Tocilizumab.Approved, Investigational
BicalutamideThe serum concentration of Bicalutamide can be decreased when it is combined with Tocilizumab.Approved
BictegravirThe serum concentration of Bictegravir can be decreased when it is combined with Tocilizumab.Approved, Investigational
BioallethrinThe serum concentration of Bioallethrin can be decreased when it is combined with Tocilizumab.Approved, Experimental
BisoprololThe serum concentration of Bisoprolol can be decreased when it is combined with Tocilizumab.Approved
BlonanserinThe serum concentration of Blonanserin can be decreased when it is combined with Tocilizumab.Approved, Investigational
BoceprevirThe serum concentration of Boceprevir can be decreased when it is combined with Tocilizumab.Approved, Withdrawn
BortezomibThe serum concentration of Bortezomib can be decreased when it is combined with Tocilizumab.Approved, Investigational
BosentanThe serum concentration of Bosentan can be decreased when it is combined with Tocilizumab.Approved, Investigational
BosutinibThe serum concentration of Bosutinib can be decreased when it is combined with Tocilizumab.Approved
Brentuximab vedotinThe serum concentration of Brentuximab vedotin can be decreased when it is combined with Tocilizumab.Approved, Investigational
BrexpiprazoleThe serum concentration of Brexpiprazole can be decreased when it is combined with Tocilizumab.Approved, Investigational
BrigatinibThe serum concentration of Brigatinib can be decreased when it is combined with Tocilizumab.Approved, Investigational
BrinzolamideThe serum concentration of Brinzolamide can be decreased when it is combined with Tocilizumab.Approved
BrivaracetamThe serum concentration of Brivaracetam can be decreased when it is combined with Tocilizumab.Approved, Investigational
BromazepamThe serum concentration of Bromazepam can be decreased when it is combined with Tocilizumab.Approved, Illicit, Investigational
BromocriptineThe serum concentration of Bromocriptine can be decreased when it is combined with Tocilizumab.Approved, Investigational
BrompheniramineThe serum concentration of Brompheniramine can be decreased when it is combined with Tocilizumab.Approved
BudesonideThe serum concentration of Budesonide can be decreased when it is combined with Tocilizumab.Approved
BupivacaineThe serum concentration of Bupivacaine can be decreased when it is combined with Tocilizumab.Approved, Investigational
BuprenorphineThe serum concentration of Buprenorphine can be decreased when it is combined with Tocilizumab.Approved, Illicit, Investigational, Vet Approved
BupropionThe serum concentration of Bupropion can be decreased when it is combined with Tocilizumab.Approved
BuspironeThe serum concentration of Buspirone can be decreased when it is combined with Tocilizumab.Approved, Investigational
BusulfanThe serum concentration of Busulfan can be decreased when it is combined with Tocilizumab.Approved, Investigational
CabazitaxelThe serum concentration of Cabazitaxel can be decreased when it is combined with Tocilizumab.Approved
CabergolineThe serum concentration of Cabergoline can be decreased when it is combined with Tocilizumab.Approved
CabozantinibThe serum concentration of Cabozantinib can be decreased when it is combined with Tocilizumab.Approved, Investigational
CaffeineThe serum concentration of Caffeine can be decreased when it is combined with Tocilizumab.Approved
CalcitriolThe serum concentration of Calcitriol can be decreased when it is combined with Tocilizumab.Approved, Nutraceutical
CanagliflozinThe serum concentration of Canagliflozin can be decreased when it is combined with Tocilizumab.Approved
CannabidiolThe serum concentration of Cannabidiol can be decreased when it is combined with Tocilizumab.Approved, Investigational
CarbamazepineThe serum concentration of Carbamazepine can be decreased when it is combined with Tocilizumab.Approved, Investigational
CarbinoxamineThe serum concentration of Carbinoxamine can be decreased when it is combined with Tocilizumab.Approved
CariprazineThe serum concentration of Cariprazine can be decreased when it is combined with Tocilizumab.Approved, Investigational
CarvedilolThe serum concentration of Carvedilol can be decreased when it is combined with Tocilizumab.Approved, Investigational
CelecoxibThe serum concentration of Celecoxib can be decreased when it is combined with Tocilizumab.Approved, Investigational
CeliprololThe serum concentration of Celiprolol can be decreased when it is combined with Tocilizumab.Approved, Investigational
CephalexinThe serum concentration of Cephalexin can be decreased when it is combined with Tocilizumab.Approved, Investigational, Vet Approved
CerivastatinThe serum concentration of Cerivastatin can be decreased when it is combined with Tocilizumab.Approved, Withdrawn
Certolizumab pegolTocilizumab may increase the immunosuppressive activities of Certolizumab pegol.Approved
CevimelineThe serum concentration of Cevimeline can be decreased when it is combined with Tocilizumab.Approved
Chenodeoxycholic acidThe serum concentration of Chenodeoxycholic acid can be decreased when it is combined with Tocilizumab.Approved
ChlordiazepoxideThe serum concentration of Chlordiazepoxide can be decreased when it is combined with Tocilizumab.Approved, Illicit, Investigational
ChloroquineThe serum concentration of Chloroquine can be decreased when it is combined with Tocilizumab.Approved, Investigational, Vet Approved
ChlorphenamineThe serum concentration of Chlorphenamine can be decreased when it is combined with Tocilizumab.Approved
ChlorpromazineThe serum concentration of Chlorpromazine can be decreased when it is combined with Tocilizumab.Approved, Investigational, Vet Approved
ChlorzoxazoneThe serum concentration of Chlorzoxazone can be decreased when it is combined with Tocilizumab.Approved
CholecalciferolThe serum concentration of Cholecalciferol can be decreased when it is combined with Tocilizumab.Approved, Nutraceutical
CiclesonideThe serum concentration of Ciclesonide can be decreased when it is combined with Tocilizumab.Approved, Investigational
CilostazolThe serum concentration of Cilostazol can be decreased when it is combined with Tocilizumab.Approved, Investigational
CinacalcetThe serum concentration of Cinacalcet can be decreased when it is combined with Tocilizumab.Approved
CisaprideThe serum concentration of Cisapride can be decreased when it is combined with Tocilizumab.Approved, Investigational, Withdrawn
CitalopramThe serum concentration of Citalopram can be decreased when it is combined with Tocilizumab.Approved
ClarithromycinThe serum concentration of Clarithromycin can be decreased when it is combined with Tocilizumab.Approved
ClindamycinThe serum concentration of Clindamycin can be decreased when it is combined with Tocilizumab.Approved, Vet Approved
ClobazamThe serum concentration of Clobazam can be decreased when it is combined with Tocilizumab.Approved, Illicit
ClofazimineThe serum concentration of Clofazimine can be decreased when it is combined with Tocilizumab.Approved, Investigational
ClofibrateThe serum concentration of Clofibrate can be decreased when it is combined with Tocilizumab.Approved, Investigational
clomethiazoleThe serum concentration of clomethiazole can be decreased when it is combined with Tocilizumab.Investigational
ClomipramineThe serum concentration of Clomipramine can be decreased when it is combined with Tocilizumab.Approved, Investigational, Vet Approved
ClonazepamThe serum concentration of Clonazepam can be decreased when it is combined with Tocilizumab.Approved, Illicit
ClonidineThe serum concentration of Clonidine can be decreased when it is combined with Tocilizumab.Approved
ClopidogrelThe serum concentration of Clopidogrel can be decreased when it is combined with Tocilizumab.Approved
ClorazepateThe serum concentration of Clorazepate can be decreased when it is combined with Tocilizumab.Approved, Illicit
Clostridium tetani toxoid antigen (formaldehyde inactivated)The risk or severity of adverse effects can be increased when Tocilizumab is combined with Clostridium tetani toxoid antigen (formaldehyde inactivated).Approved
ClotiazepamThe serum concentration of Clotiazepam can be decreased when it is combined with Tocilizumab.Approved, Illicit
ClozapineThe serum concentration of Clozapine can be decreased when it is combined with Tocilizumab.Approved
CocaineThe serum concentration of Cocaine can be decreased when it is combined with Tocilizumab.Approved, Illicit
CodeineThe serum concentration of Codeine can be decreased when it is combined with Tocilizumab.Approved, Illicit
ColchicineThe serum concentration of Colchicine can be decreased when it is combined with Tocilizumab.Approved
ConivaptanThe serum concentration of Conivaptan can be decreased when it is combined with Tocilizumab.Approved, Investigational
Conjugated estrogensThe serum concentration of Conjugated estrogens can be decreased when it is combined with Tocilizumab.Approved
CopanlisibThe serum concentration of Copanlisib can be decreased when it is combined with Tocilizumab.Approved, Investigational
Cortisone acetateThe serum concentration of Cortisone acetate can be decreased when it is combined with Tocilizumab.Approved, Investigational
Corynebacterium diphtheriae toxoid antigen (formaldehyde inactivated)The risk or severity of adverse effects can be increased when Tocilizumab is combined with Corynebacterium diphtheriae toxoid antigen (formaldehyde inactivated).Approved
CrizotinibThe serum concentration of Crizotinib can be decreased when it is combined with Tocilizumab.Approved
CyclobenzaprineThe serum concentration of Cyclobenzaprine can be decreased when it is combined with Tocilizumab.Approved
CyclophosphamideThe serum concentration of Cyclophosphamide can be decreased when it is combined with Tocilizumab.Approved, Investigational
CyclosporineThe serum concentration of Cyclosporine can be decreased when it is combined with Tocilizumab.Approved, Investigational, Vet Approved
CytarabineThe serum concentration of Cytarabine can be decreased when it is combined with Tocilizumab.Approved, Investigational
DabrafenibThe serum concentration of Dabrafenib can be decreased when it is combined with Tocilizumab.Approved, Investigational
DaclatasvirThe serum concentration of Daclatasvir can be decreased when it is combined with Tocilizumab.Approved, Investigational
DantroleneThe serum concentration of Dantrolene can be decreased when it is combined with Tocilizumab.Approved, Investigational
DapagliflozinThe serum concentration of Dapagliflozin can be decreased when it is combined with Tocilizumab.Approved
DapsoneThe serum concentration of Dapsone can be decreased when it is combined with Tocilizumab.Approved, Investigational
DarifenacinThe serum concentration of Darifenacin can be decreased when it is combined with Tocilizumab.Approved, Investigational
DarunavirThe serum concentration of Darunavir can be decreased when it is combined with Tocilizumab.Approved
DasabuvirThe serum concentration of Dasabuvir can be decreased when it is combined with Tocilizumab.Approved
DasatinibThe serum concentration of Dasatinib can be decreased when it is combined with Tocilizumab.Approved, Investigational
DaunorubicinThe serum concentration of Daunorubicin can be decreased when it is combined with Tocilizumab.Approved
DeflazacortThe serum concentration of Deflazacort can be decreased when it is combined with Tocilizumab.Approved, Investigational
DelamanidThe serum concentration of Delamanid can be decreased when it is combined with Tocilizumab.Approved, Investigational
DelavirdineThe serum concentration of Delavirdine can be decreased when it is combined with Tocilizumab.Approved
DenosumabThe risk or severity of adverse effects can be increased when Denosumab is combined with Tocilizumab.Approved
DesvenlafaxineThe serum concentration of Desvenlafaxine can be decreased when it is combined with Tocilizumab.Approved, Investigational
DeutetrabenazineThe serum concentration of Deutetrabenazine can be decreased when it is combined with Tocilizumab.Approved, Investigational
DexamethasoneThe serum concentration of Dexamethasone can be decreased when it is combined with Tocilizumab.Approved, Investigational, Vet Approved
Dexchlorpheniramine maleateThe serum concentration of Dexchlorpheniramine maleate can be decreased when it is combined with Tocilizumab.Approved
DexlansoprazoleThe serum concentration of Dexlansoprazole can be decreased when it is combined with Tocilizumab.Approved, Investigational
DextromethorphanThe serum concentration of Dextromethorphan can be decreased when it is combined with Tocilizumab.Approved
DextropropoxypheneThe serum concentration of Dextropropoxyphene can be decreased when it is combined with Tocilizumab.Approved, Illicit, Investigational, Withdrawn
DiazepamThe serum concentration of Diazepam can be decreased when it is combined with Tocilizumab.Approved, Illicit, Investigational, Vet Approved
DiclofenacThe serum concentration of Diclofenac can be decreased when it is combined with Tocilizumab.Approved, Vet Approved
DienogestThe serum concentration of Dienogest can be decreased when it is combined with Tocilizumab.Approved
DigitoxinThe serum concentration of Digitoxin can be decreased when it is combined with Tocilizumab.Approved, Investigational
DigoxinThe serum concentration of Digoxin can be decreased when it is combined with Tocilizumab.Approved
Dihydro-alpha-ergocryptineThe serum concentration of Dihydro-alpha-ergocryptine can be decreased when it is combined with Tocilizumab.Approved
DihydrocodeineThe serum concentration of Dihydrocodeine can be decreased when it is combined with Tocilizumab.Approved, Illicit
DihydroergotamineThe serum concentration of Dihydroergotamine can be decreased when it is combined with Tocilizumab.Approved, Investigational
DiltiazemThe serum concentration of Diltiazem can be decreased when it is combined with Tocilizumab.Approved, Investigational
DisopyramideThe serum concentration of Disopyramide can be decreased when it is combined with Tocilizumab.Approved
DisulfiramThe serum concentration of Disulfiram can be decreased when it is combined with Tocilizumab.Approved
DocetaxelThe serum concentration of Docetaxel can be decreased when it is combined with Tocilizumab.Approved, Investigational
DofetilideThe serum concentration of Dofetilide can be decreased when it is combined with Tocilizumab.Approved, Investigational
DolasetronThe serum concentration of Dolasetron can be decreased when it is combined with Tocilizumab.Approved, Investigational
DomperidoneThe serum concentration of Domperidone can be decreased when it is combined with Tocilizumab.Approved, Investigational, Vet Approved
DonepezilThe serum concentration of Donepezil can be decreased when it is combined with Tocilizumab.Approved
DorzolamideThe serum concentration of Dorzolamide can be decreased when it is combined with Tocilizumab.Approved
DoxepinThe serum concentration of Doxepin can be decreased when it is combined with Tocilizumab.Approved, Investigational
DoxorubicinThe serum concentration of Doxorubicin can be decreased when it is combined with Tocilizumab.Approved, Investigational
DronabinolThe serum concentration of Dronabinol can be decreased when it is combined with Tocilizumab.Approved, Illicit
DronedaroneThe serum concentration of Dronedarone can be decreased when it is combined with Tocilizumab.Approved
DutasterideThe serum concentration of Dutasteride can be decreased when it is combined with Tocilizumab.Approved, Investigational
EfavirenzThe serum concentration of Efavirenz can be decreased when it is combined with Tocilizumab.Approved, Investigational
ElbasvirThe serum concentration of Elbasvir can be decreased when it is combined with Tocilizumab.Approved
EletriptanThe serum concentration of Eletriptan can be decreased when it is combined with Tocilizumab.Approved, Investigational
EliglustatThe serum concentration of Eliglustat can be decreased when it is combined with Tocilizumab.Approved
ElvitegravirThe serum concentration of Elvitegravir can be decreased when it is combined with Tocilizumab.Approved
EnalaprilThe serum concentration of Enalapril can be decreased when it is combined with Tocilizumab.Approved, Vet Approved
EnasidenibThe serum concentration of Enasidenib can be decreased when it is combined with Tocilizumab.Approved, Investigational
EnzalutamideThe serum concentration of Enzalutamide can be decreased when it is combined with Tocilizumab.Approved
EpinastineThe serum concentration of Epinastine can be decreased when it is combined with Tocilizumab.Approved, Investigational
EplerenoneThe serum concentration of Eplerenone can be decreased when it is combined with Tocilizumab.Approved
ErgocalciferolThe serum concentration of Ergocalciferol can be decreased when it is combined with Tocilizumab.Approved, Nutraceutical
Ergoloid mesylateThe serum concentration of Ergoloid mesylate can be decreased when it is combined with Tocilizumab.Approved
ErgonovineThe serum concentration of Ergonovine can be decreased when it is combined with Tocilizumab.Approved
ErgotamineThe serum concentration of Ergotamine can be decreased when it is combined with Tocilizumab.Approved
ErlotinibThe serum concentration of Erlotinib can be decreased when it is combined with Tocilizumab.Approved, Investigational
ErythromycinThe serum concentration of Erythromycin can be decreased when it is combined with Tocilizumab.Approved, Investigational, Vet Approved
EscitalopramThe serum concentration of Escitalopram can be decreased when it is combined with Tocilizumab.Approved, Investigational
EsomeprazoleThe serum concentration of Esomeprazole can be decreased when it is combined with Tocilizumab.Approved, Investigational
EstazolamThe serum concentration of Estazolam can be decreased when it is combined with Tocilizumab.Approved, Illicit
EstradiolThe serum concentration of Estradiol can be decreased when it is combined with Tocilizumab.Approved, Investigational, Vet Approved
Estradiol acetateThe serum concentration of Estradiol acetate can be decreased when it is combined with Tocilizumab.Approved, Investigational, Vet Approved
Estradiol benzoateThe serum concentration of Estradiol benzoate can be decreased when it is combined with Tocilizumab.Approved, Investigational, Vet Approved
Estradiol cypionateThe serum concentration of Estradiol cypionate can be decreased when it is combined with Tocilizumab.Approved, Investigational, Vet Approved
Estradiol dienanthateThe serum concentration of Estradiol dienanthate can be decreased when it is combined with Tocilizumab.Approved, Investigational, Vet Approved
Estradiol valerateThe serum concentration of Estradiol valerate can be decreased when it is combined with Tocilizumab.Approved, Investigational, Vet Approved
EstramustineThe serum concentration of Estramustine can be decreased when it is combined with Tocilizumab.Approved, Investigational
Estrogens, esterifiedThe serum concentration of Estrogens, esterified can be decreased when it is combined with Tocilizumab.Approved
EstroneThe serum concentration of Estrone can be decreased when it is combined with Tocilizumab.Approved
Estrone sulfateThe serum concentration of Estrone sulfate can be decreased when it is combined with Tocilizumab.Approved
EszopicloneThe serum concentration of Eszopiclone can be decreased when it is combined with Tocilizumab.Approved, Investigational
EtanerceptTocilizumab may increase the immunosuppressive activities of Etanercept.Approved, Investigational
EthanolThe serum concentration of Ethanol can be decreased when it is combined with Tocilizumab.Approved
Ethinyl EstradiolThe serum concentration of Ethinyl Estradiol can be decreased when it is combined with Tocilizumab.Approved
EthosuximideThe serum concentration of Ethosuximide can be decreased when it is combined with Tocilizumab.Approved
EthylmorphineThe serum concentration of Ethylmorphine can be decreased when it is combined with Tocilizumab.Approved, Illicit
EtizolamThe serum concentration of Etizolam can be decreased when it is combined with Tocilizumab.Approved
EtonogestrelThe serum concentration of Etonogestrel can be decreased when it is combined with Tocilizumab.Approved, Investigational
EtoposideThe serum concentration of Etoposide can be decreased when it is combined with Tocilizumab.Approved
EtoricoxibThe serum concentration of Etoricoxib can be decreased when it is combined with Tocilizumab.Approved, Investigational
EtravirineThe serum concentration of Etravirine can be decreased when it is combined with Tocilizumab.Approved
EverolimusThe serum concentration of Everolimus can be decreased when it is combined with Tocilizumab.Approved
ExemestaneThe serum concentration of Exemestane can be decreased when it is combined with Tocilizumab.Approved, Investigational
FamciclovirThe serum concentration of Famciclovir can be decreased when it is combined with Tocilizumab.Approved, Investigational
FelbamateThe serum concentration of Felbamate can be decreased when it is combined with Tocilizumab.Approved
FelodipineThe serum concentration of Felodipine can be decreased when it is combined with Tocilizumab.Approved, Investigational
FenofibrateThe serum concentration of Fenofibrate can be decreased when it is combined with Tocilizumab.Approved
FentanylThe serum concentration of Fentanyl can be decreased when it is combined with Tocilizumab.Approved, Illicit, Investigational, Vet Approved
FesoterodineThe serum concentration of Fesoterodine can be decreased when it is combined with Tocilizumab.Approved
FinasterideThe serum concentration of Finasteride can be decreased when it is combined with Tocilizumab.Approved
FingolimodTocilizumab may increase the immunosuppressive activities of Fingolimod.Approved, Investigational
FlibanserinThe serum concentration of Flibanserin can be decreased when it is combined with Tocilizumab.Approved, Investigational
FlunisolideThe serum concentration of Flunisolide can be decreased when it is combined with Tocilizumab.Approved, Investigational
FlunitrazepamThe serum concentration of Flunitrazepam can be decreased when it is combined with Tocilizumab.Approved, Illicit
FluorometholoneThe serum concentration of Fluorometholone can be decreased when it is combined with Tocilizumab.Approved, Investigational
FluoxetineThe serum concentration of Fluoxetine can be decreased when it is combined with Tocilizumab.Approved, Vet Approved
FlurazepamThe serum concentration of Flurazepam can be decreased when it is combined with Tocilizumab.Approved, Illicit, Investigational
FlutamideThe serum concentration of Flutamide can be decreased when it is combined with Tocilizumab.Approved, Investigational
Fluticasone furoateThe serum concentration of Fluticasone furoate can be decreased when it is combined with Tocilizumab.Approved
Fluticasone propionateThe serum concentration of Fluticasone propionate can be decreased when it is combined with Tocilizumab.Approved
FluvastatinThe serum concentration of Fluvastatin can be decreased when it is combined with Tocilizumab.Approved
FosamprenavirThe serum concentration of Fosamprenavir can be decreased when it is combined with Tocilizumab.Approved
FosnetupitantThe serum concentration of Fosnetupitant can be decreased when it is combined with Tocilizumab.Approved
FostamatinibThe serum concentration of Fostamatinib can be decreased when it is combined with Tocilizumab.Approved, Investigational
FulvestrantThe serum concentration of Fulvestrant can be decreased when it is combined with Tocilizumab.Approved, Investigational
G17DTThe risk or severity of adverse effects can be increased when Tocilizumab is combined with G17DT.Investigational
GalantamineThe serum concentration of Galantamine can be decreased when it is combined with Tocilizumab.Approved
GefitinibThe serum concentration of Gefitinib can be decreased when it is combined with Tocilizumab.Approved, Investigational
GemfibrozilThe serum concentration of Gemfibrozil can be decreased when it is combined with Tocilizumab.Approved
GI-5005The risk or severity of adverse effects can be increased when Tocilizumab is combined with GI-5005.Investigational
GlipizideThe serum concentration of Glipizide can be decreased when it is combined with Tocilizumab.Approved, Investigational
GlyburideThe serum concentration of Glyburide can be decreased when it is combined with Tocilizumab.Approved
GolimumabTocilizumab may increase the immunosuppressive activities of Golimumab.Approved
GranisetronThe serum concentration of Granisetron can be decreased when it is combined with Tocilizumab.Approved, Investigational
GrazoprevirThe serum concentration of Grazoprevir can be decreased when it is combined with Tocilizumab.Approved
GrepafloxacinThe serum concentration of Grepafloxacin can be decreased when it is combined with Tocilizumab.Approved, Investigational, Withdrawn
GuanfacineThe serum concentration of Guanfacine can be decreased when it is combined with Tocilizumab.Approved, Investigational
HalofantrineThe serum concentration of Halofantrine can be decreased when it is combined with Tocilizumab.Approved
HaloperidolThe serum concentration of Haloperidol can be decreased when it is combined with Tocilizumab.Approved
HalothaneThe serum concentration of Halothane can be decreased when it is combined with Tocilizumab.Approved, Vet Approved
Hepatitis A VaccineThe risk or severity of adverse effects can be increased when Tocilizumab is combined with Hepatitis A Vaccine.Approved
Hepatitis B Vaccine (Recombinant)The risk or severity of adverse effects can be increased when Tocilizumab is combined with Hepatitis B Vaccine (Recombinant).Approved, Withdrawn
HexobarbitalThe serum concentration of Hexobarbital can be decreased when it is combined with Tocilizumab.Approved
HistamineThe serum concentration of Histamine can be decreased when it is combined with Tocilizumab.Approved, Investigational
Human rabies virus immune globulinThe risk or severity of adverse effects can be increased when Tocilizumab is combined with Human rabies virus immune globulin.Approved
HydrocodoneThe serum concentration of Hydrocodone can be decreased when it is combined with Tocilizumab.Approved, Illicit
HydrocortisoneThe serum concentration of Hydrocortisone can be decreased when it is combined with Tocilizumab.Approved, Vet Approved
HydromorphoneThe serum concentration of Hydromorphone can be decreased when it is combined with Tocilizumab.Approved, Illicit
Hydroxyprogesterone caproateThe serum concentration of Hydroxyprogesterone caproate can be decreased when it is combined with Tocilizumab.Approved, Investigational
IbrutinibThe serum concentration of Ibrutinib can be decreased when it is combined with Tocilizumab.Approved
IcotinibThe serum concentration of Icotinib can be decreased when it is combined with Tocilizumab.Approved, Investigational
IfosfamideThe serum concentration of Ifosfamide can be decreased when it is combined with Tocilizumab.Approved
IloperidoneThe serum concentration of Iloperidone can be decreased when it is combined with Tocilizumab.Approved
ImatinibThe serum concentration of Imatinib can be decreased when it is combined with Tocilizumab.Approved
ImidafenacinThe serum concentration of Imidafenacin can be decreased when it is combined with Tocilizumab.Approved, Investigational
ImipramineThe serum concentration of Imipramine can be decreased when it is combined with Tocilizumab.Approved
ImiquimodThe serum concentration of Imiquimod can be decreased when it is combined with Tocilizumab.Approved, Investigational
IndacaterolThe serum concentration of Indacaterol can be decreased when it is combined with Tocilizumab.Approved
IndapamideThe serum concentration of Indapamide can be decreased when it is combined with Tocilizumab.Approved
IndinavirThe serum concentration of Indinavir can be decreased when it is combined with Tocilizumab.Approved
InfliximabThe risk or severity of adverse effects can be increased when Tocilizumab is combined with Infliximab.Approved
INGN 201The risk or severity of adverse effects can be increased when Tocilizumab is combined with INGN 201.Investigational
INGN 225The risk or severity of adverse effects can be increased when Tocilizumab is combined with INGN 225.Investigational
IpecacThe serum concentration of Ipecac can be decreased when it is combined with Tocilizumab.Approved, Withdrawn
IpratropiumThe serum concentration of Ipratropium bromide can be decreased when it is combined with Tocilizumab.Approved
IrinotecanThe serum concentration of Irinotecan can be decreased when it is combined with Tocilizumab.Approved, Investigational
IsavuconazoleThe serum concentration of Isavuconazole can be decreased when it is combined with Tocilizumab.Approved, Investigational
IsavuconazoniumThe serum concentration of Isavuconazonium can be decreased when it is combined with Tocilizumab.Approved, Investigational
Isosorbide DinitrateThe serum concentration of Isosorbide Dinitrate can be decreased when it is combined with Tocilizumab.Approved, Investigational
Isosorbide MononitrateThe serum concentration of Isosorbide Mononitrate can be decreased when it is combined with Tocilizumab.Approved
IsradipineThe serum concentration of Isradipine can be decreased when it is combined with Tocilizumab.Approved, Investigational
ItraconazoleThe serum concentration of Itraconazole can be decreased when it is combined with Tocilizumab.Approved, Investigational
IvabradineThe serum concentration of Ivabradine can be decreased when it is combined with Tocilizumab.Approved
IvacaftorThe serum concentration of Ivacaftor can be decreased when it is combined with Tocilizumab.Approved
IvermectinThe serum concentration of Ivermectin can be decreased when it is combined with Tocilizumab.Approved, Investigational, Vet Approved
IxabepiloneThe serum concentration of Ixabepilone can be decreased when it is combined with Tocilizumab.Approved, Investigational
IxazomibThe serum concentration of Ixazomib can be decreased when it is combined with Tocilizumab.Approved, Investigational
Japanese encephalitis virus strain sa 14-14-2 antigen (formaldehyde inactivated)The risk or severity of adverse effects can be increased when Tocilizumab is combined with Japanese encephalitis virus strain sa 14-14-2 antigen (formaldehyde inactivated).Approved
KetamineThe serum concentration of Ketamine can be decreased when it is combined with Tocilizumab.Approved, Vet Approved
KetazolamThe serum concentration of Ketazolam can be decreased when it is combined with Tocilizumab.Approved
KetobemidoneThe serum concentration of Ketobemidone can be decreased when it is combined with Tocilizumab.Approved, Investigational
KetoconazoleThe serum concentration of Ketoconazole can be decreased when it is combined with Tocilizumab.Approved, Investigational
LacidipineThe serum concentration of Lacidipine can be decreased when it is combined with Tocilizumab.Approved, Investigational
LansoprazoleThe serum concentration of Lansoprazole can be decreased when it is combined with Tocilizumab.Approved, Investigational
LapatinibThe serum concentration of Lapatinib can be decreased when it is combined with Tocilizumab.Approved, Investigational
LaquinimodThe serum concentration of Laquinimod can be decreased when it is combined with Tocilizumab.Investigational
LeflunomideThe risk or severity of adverse effects can be increased when Tocilizumab is combined with Leflunomide.Approved, Investigational
LenvatinibThe serum concentration of Lenvatinib can be decreased when it is combined with Tocilizumab.Approved, Investigational
LercanidipineThe serum concentration of Lercanidipine can be decreased when it is combined with Tocilizumab.Approved, Investigational
LetrozoleThe serum concentration of Letrozole can be decreased when it is combined with Tocilizumab.Approved, Investigational
LevobupivacaineThe serum concentration of Levobupivacaine can be decreased when it is combined with Tocilizumab.Approved, Investigational
LevocetirizineThe serum concentration of Levocetirizine can be decreased when it is combined with Tocilizumab.Approved
Levomethadyl AcetateThe serum concentration of Levomethadyl Acetate can be decreased when it is combined with Tocilizumab.Approved, Investigational
LevomilnacipranThe serum concentration of Levomilnacipran can be decreased when it is combined with Tocilizumab.Approved, Investigational
LevonorgestrelThe serum concentration of Levonorgestrel can be decreased when it is combined with Tocilizumab.Approved, Investigational
LevothyroxineThe serum concentration of Levothyroxine can be decreased when it is combined with Tocilizumab.Approved
LidocaineThe serum concentration of Lidocaine can be decreased when it is combined with Tocilizumab.Approved, Vet Approved
LisurideThe serum concentration of Lisuride can be decreased when it is combined with Tocilizumab.Approved, Investigational
LomitapideThe serum concentration of Lomitapide can be decreased when it is combined with Tocilizumab.Approved, Investigational
LoperamideThe serum concentration of Loperamide can be decreased when it is combined with Tocilizumab.Approved
LopinavirThe serum concentration of Lopinavir can be decreased when it is combined with Tocilizumab.Approved
LoratadineThe serum concentration of Loratadine can be decreased when it is combined with Tocilizumab.Approved, Investigational
LorcaserinThe serum concentration of Lorcaserin can be decreased when it is combined with Tocilizumab.Approved
LorpiprazoleThe serum concentration of Lorpiprazole can be decreased when it is combined with Tocilizumab.Approved
LosartanThe serum concentration of Losartan can be decreased when it is combined with Tocilizumab.Approved
LovastatinThe serum concentration of Lovastatin can be decreased when it is combined with Tocilizumab.Approved, Investigational
LumefantrineThe serum concentration of Lumefantrine can be decreased when it is combined with Tocilizumab.Approved
LurasidoneThe serum concentration of Lurasidone can be decreased when it is combined with Tocilizumab.Approved, Investigational
MacimorelinThe serum concentration of Macimorelin can be decreased when it is combined with Tocilizumab.Approved, Investigational
MacitentanThe serum concentration of Macitentan can be decreased when it is combined with Tocilizumab.Approved
MaravirocThe serum concentration of Maraviroc can be decreased when it is combined with Tocilizumab.Approved, Investigational
MebendazoleThe serum concentration of Mebendazole can be decreased when it is combined with Tocilizumab.Approved, Vet Approved
Medical CannabisThe serum concentration of Medical Cannabis can be decreased when it is combined with Tocilizumab.Experimental, Investigational
Medroxyprogesterone acetateThe serum concentration of Medroxyprogesterone acetate can be decreased when it is combined with Tocilizumab.Approved, Investigational
MefloquineThe serum concentration of Mefloquine can be decreased when it is combined with Tocilizumab.Approved, Investigational
MeloxicamThe serum concentration of Meloxicam can be decreased when it is combined with Tocilizumab.Approved, Vet Approved
MethadoneThe serum concentration of Methadone can be decreased when it is combined with Tocilizumab.Approved
MethaqualoneThe serum concentration of Methaqualone can be decreased when it is combined with Tocilizumab.Illicit, Withdrawn
MethoxsalenThe serum concentration of Methoxsalen can be decreased when it is combined with Tocilizumab.Approved
MethoxyfluraneThe serum concentration of Methoxyflurane can be decreased when it is combined with Tocilizumab.Approved, Investigational, Vet Approved
MethylprednisoloneThe serum concentration of Methylprednisolone can be decreased when it is combined with Tocilizumab.Approved, Vet Approved
MethyltestosteroneThe serum concentration of Methyltestosterone can be decreased when it is combined with Tocilizumab.Approved
MetronidazoleThe serum concentration of Metronidazole can be decreased when it is combined with Tocilizumab.Approved
MexiletineThe serum concentration of Mexiletine can be decreased when it is combined with Tocilizumab.Approved, Investigational
MianserinThe serum concentration of Mianserin can be decreased when it is combined with Tocilizumab.Approved, Investigational
MibefradilThe serum concentration of Mibefradil can be decreased when it is combined with Tocilizumab.Investigational, Withdrawn
MiconazoleThe serum concentration of Miconazole can be decreased when it is combined with Tocilizumab.Approved, Investigational, Vet Approved
MidazolamThe serum concentration of Midazolam can be decreased when it is combined with Tocilizumab.Approved, Illicit
MidecamycinThe serum concentration of Midecamycin can be decreased when it is combined with Tocilizumab.Approved
MidostaurinThe serum concentration of Midostaurin can be decreased when it is combined with Tocilizumab.Approved, Investigational
MifepristoneThe serum concentration of Mifepristone can be decreased when it is combined with Tocilizumab.Approved, Investigational
MirabegronThe serum concentration of Mirabegron can be decreased when it is combined with Tocilizumab.Approved
MirtazapineThe serum concentration of Mirtazapine can be decreased when it is combined with Tocilizumab.Approved
ModafinilThe serum concentration of Modafinil can be decreased when it is combined with Tocilizumab.Approved, Investigational
MontelukastThe serum concentration of Montelukast can be decreased when it is combined with Tocilizumab.Approved
MorphineThe serum concentration of Morphine can be decreased when it is combined with Tocilizumab.Approved, Investigational
Mycophenolate mofetilThe serum concentration of Mycophenolate mofetil can be decreased when it is combined with Tocilizumab.Approved, Investigational
NabiximolsThe serum concentration of Nabiximols can be decreased when it is combined with Tocilizumab.Approved, Investigational
NaloxegolThe serum concentration of Naloxegol can be decreased when it is combined with Tocilizumab.Approved
NaloxoneThe serum concentration of Naloxone can be decreased when it is combined with Tocilizumab.Approved, Vet Approved
NatalizumabThe risk or severity of adverse effects can be increased when Tocilizumab is combined with Natalizumab.Approved, Investigational
NateglinideThe serum concentration of Nateglinide can be decreased when it is combined with Tocilizumab.Approved, Investigational
NefazodoneThe serum concentration of Nefazodone can be decreased when it is combined with Tocilizumab.Approved, Withdrawn
NelfinavirThe serum concentration of Nelfinavir can be decreased when it is combined with Tocilizumab.Approved
NeratinibThe serum concentration of Neratinib can be decreased when it is combined with Tocilizumab.Approved, Investigational
NevirapineThe serum concentration of Nevirapine can be decreased when it is combined with Tocilizumab.Approved
NicardipineThe serum concentration of Nicardipine can be decreased when it is combined with Tocilizumab.Approved, Investigational
NicotineThe serum concentration of Nicotine can be decreased when it is combined with Tocilizumab.Approved
NifedipineThe serum concentration of Nifedipine can be decreased when it is combined with Tocilizumab.Approved
NilotinibThe serum concentration of Nilotinib can be decreased when it is combined with Tocilizumab.Approved, Investigational
NilvadipineThe serum concentration of Nilvadipine can be decreased when it is combined with Tocilizumab.Approved, Investigational
NimodipineThe serum concentration of Nimodipine can be decreased when it is combined with Tocilizumab.Approved, Investigational
NisoldipineThe serum concentration of Nisoldipine can be decreased when it is combined with Tocilizumab.Approved
NitrazepamThe serum concentration of Nitrazepam can be decreased when it is combined with Tocilizumab.Approved
NitrendipineThe serum concentration of Nitrendipine can be decreased when it is combined with Tocilizumab.Approved, Investigational
NorethisteroneThe serum concentration of Norethisterone can be decreased when it is combined with Tocilizumab.Approved
NorgestrelThe serum concentration of Norgestrel can be decreased when it is combined with Tocilizumab.Approved
NortriptylineThe serum concentration of Nortriptyline can be decreased when it is combined with Tocilizumab.Approved
OcrelizumabOcrelizumab may increase the immunosuppressive activities of Tocilizumab.Approved, Investigational
OdanacatibThe serum concentration of Odanacatib can be decreased when it is combined with Tocilizumab.Investigational
OlaparibThe serum concentration of Olaparib can be decreased when it is combined with Tocilizumab.Approved
OlopatadineThe serum concentration of Olopatadine can be decreased when it is combined with Tocilizumab.Approved
OmeprazoleThe serum concentration of Omeprazole can be decreased when it is combined with Tocilizumab.Approved, Investigational, Vet Approved
OndansetronThe serum concentration of Ondansetron can be decreased when it is combined with Tocilizumab.Approved
OpiumThe serum concentration of Opium can be decreased when it is combined with Tocilizumab.Approved, Illicit
OrphenadrineThe serum concentration of Orphenadrine can be decreased when it is combined with Tocilizumab.Approved
OspemifeneThe serum concentration of Ospemifene can be decreased when it is combined with Tocilizumab.Approved, Investigational
OxazepamThe serum concentration of Oxazepam can be decreased when it is combined with Tocilizumab.Approved
OxybutyninThe serum concentration of Oxybutynin can be decreased when it is combined with Tocilizumab.Approved, Investigational
OxycodoneThe serum concentration of Oxycodone can be decreased when it is combined with Tocilizumab.Approved, Illicit, Investigational
OxymorphoneThe serum concentration of Oxymorphone can be decreased when it is combined with Tocilizumab.Approved, Investigational, Vet Approved
PaclitaxelThe serum concentration of Paclitaxel can be decreased when it is combined with Tocilizumab.Approved, Vet Approved
PalbociclibThe serum concentration of Palbociclib can be decreased when it is combined with Tocilizumab.Approved, Investigational
PalonosetronThe serum concentration of Palonosetron can be decreased when it is combined with Tocilizumab.Approved, Investigational
PanobinostatThe serum concentration of Panobinostat can be decreased when it is combined with Tocilizumab.Approved, Investigational
PantoprazoleThe serum concentration of Pantoprazole can be decreased when it is combined with Tocilizumab.Approved
ParamethadioneThe serum concentration of Paramethadione can be decreased when it is combined with Tocilizumab.Approved
ParamethasoneThe serum concentration of Paramethasone can be decreased when it is combined with Tocilizumab.Approved
ParecoxibThe serum concentration of Parecoxib can be decreased when it is combined with Tocilizumab.Approved
ParicalcitolThe serum concentration of Paricalcitol can be decreased when it is combined with Tocilizumab.Approved, Investigational
ParitaprevirThe serum concentration of Paritaprevir can be decreased when it is combined with Tocilizumab.Approved, Investigational
PazopanibThe serum concentration of Pazopanib can be decreased when it is combined with Tocilizumab.Approved
PentamidineThe serum concentration of Pentamidine can be decreased when it is combined with Tocilizumab.Approved, Investigational
PerampanelThe serum concentration of Perampanel can be decreased when it is combined with Tocilizumab.Approved
PergolideThe serum concentration of Pergolide can be decreased when it is combined with Tocilizumab.Approved, Investigational, Vet Approved, Withdrawn
PerhexilineThe serum concentration of Perhexiline can be decreased when it is combined with Tocilizumab.Approved, Investigational
PermethrinThe serum concentration of Permethrin can be decreased when it is combined with Tocilizumab.Approved, Investigational
PerospironeThe serum concentration of Perospirone can be decreased when it is combined with Tocilizumab.Approved
PerphenazineThe serum concentration of Perphenazine can be decreased when it is combined with Tocilizumab.Approved
PethidineThe serum concentration of Pethidine can be decreased when it is combined with Tocilizumab.Approved
PhenacetinThe serum concentration of Phenacetin can be decreased when it is combined with Tocilizumab.Withdrawn
PhenoxybenzamineThe serum concentration of Phenoxybenzamine can be decreased when it is combined with Tocilizumab.Approved
PhenprocoumonThe serum concentration of Phenprocoumon can be decreased when it is combined with Tocilizumab.Approved, Investigational
PhenytoinThe serum concentration of Phenytoin can be decreased when it is combined with Tocilizumab.Approved, Vet Approved
PilocarpineThe serum concentration of Pilocarpine can be decreased when it is combined with Tocilizumab.Approved, Investigational
PimecrolimusThe risk or severity of adverse effects can be increased when Pimecrolimus is combined with Tocilizumab.Approved, Investigational
PimozideThe serum concentration of Pimozide can be decreased when it is combined with Tocilizumab.Approved
PinacidilThe serum concentration of Pinacidil can be decreased when it is combined with Tocilizumab.Approved
PioglitazoneThe serum concentration of Pioglitazone can be decreased when it is combined with Tocilizumab.Approved, Investigational
PiperaquineThe serum concentration of Piperaquine can be decreased when it is combined with Tocilizumab.Approved, Investigational
PipotiazineThe serum concentration of Pipotiazine can be decreased when it is combined with Tocilizumab.Approved, Investigational
PirfenidoneTocilizumab may increase the immunosuppressive activities of Pirfenidone.Approved, Investigational
PitolisantThe serum concentration of Pitolisant can be decreased when it is combined with Tocilizumab.Approved, Investigational
PodofiloxThe serum concentration of Podofilox can be decreased when it is combined with Tocilizumab.Approved
PomalidomideThe serum concentration of Pomalidomide can be decreased when it is combined with Tocilizumab.Approved
PonatinibThe serum concentration of Ponatinib can be decreased when it is combined with Tocilizumab.Approved, Investigational
PosaconazoleThe serum concentration of Posaconazole can be decreased when it is combined with Tocilizumab.Approved, Investigational, Vet Approved
PrasteroneThe serum concentration of Prasterone can be decreased when it is combined with Tocilizumab.Approved, Investigational, Nutraceutical
PrasugrelThe serum concentration of Prasugrel can be decreased when it is combined with Tocilizumab.Approved
PravastatinThe serum concentration of Pravastatin can be decreased when it is combined with Tocilizumab.Approved
PrazepamThe serum concentration of Prazepam can be decreased when it is combined with Tocilizumab.Approved, Illicit
PraziquantelThe serum concentration of Praziquantel can be decreased when it is combined with Tocilizumab.Approved, Investigational, Vet Approved
PrednisoloneThe serum concentration of Prednisolone can be decreased when it is combined with Tocilizumab.Approved, Vet Approved
PrednisoneThe serum concentration of Prednisone can be decreased when it is combined with Tocilizumab.Approved, Vet Approved
PrimaquineThe serum concentration of Primaquine can be decreased when it is combined with Tocilizumab.Approved
ProchlorperazineThe serum concentration of Prochlorperazine can be decreased when it is combined with Tocilizumab.Approved, Vet Approved
ProgesteroneThe serum concentration of Progesterone can be decreased when it is combined with Tocilizumab.Approved, Vet Approved
ProguanilThe serum concentration of Proguanil can be decreased when it is combined with Tocilizumab.Approved
PromazineThe serum concentration of Promazine can be decreased when it is combined with Tocilizumab.Approved, Vet Approved
PropafenoneThe serum concentration of Propafenone can be decreased when it is combined with Tocilizumab.Approved
PropiverineThe serum concentration of Propiverine can be decreased when it is combined with Tocilizumab.Approved, Investigational
PropofolThe serum concentration of Propofol can be decreased when it is combined with Tocilizumab.Approved, Investigational, Vet Approved
PropranololThe serum concentration of Propranolol can be decreased when it is combined with Tocilizumab.Approved, Investigational
PyrazinamideThe serum concentration of Pyrazinamide can be decreased when it is combined with Tocilizumab.Approved, Investigational
QuazepamThe serum concentration of Quazepam can be decreased when it is combined with Tocilizumab.Approved, Illicit
QuetiapineThe serum concentration of Quetiapine can be decreased when it is combined with Tocilizumab.Approved
QuinacrineThe serum concentration of Quinacrine can be decreased when it is combined with Tocilizumab.Approved, Investigational
QuinidineThe serum concentration of Quinidine can be decreased when it is combined with Tocilizumab.Approved, Investigational
QuinineThe serum concentration of Quinine can be decreased when it is combined with Tocilizumab.Approved
RabeprazoleThe serum concentration of Rabeprazole can be decreased when it is combined with Tocilizumab.Approved, Investigational
Rabies virus inactivated antigen, AThe risk or severity of adverse effects can be increased when Tocilizumab is combined with Rabies virus inactivated antigen, A.Approved, Investigational
Rabies virus inactivated antigen, AThe therapeutic efficacy of Rabies virus inactivated antigen, A can be decreased when used in combination with Tocilizumab.Approved, Investigational
RaloxifeneThe serum concentration of Raloxifene can be decreased when it is combined with Tocilizumab.Approved, Investigational
RamelteonThe serum concentration of Ramelteon can be decreased when it is combined with Tocilizumab.Approved, Investigational
RanolazineThe serum concentration of Ranolazine can be decreased when it is combined with Tocilizumab.Approved, Investigational
ReboxetineThe serum concentration of Reboxetine can be decreased when it is combined with Tocilizumab.Approved, Investigational
RegorafenibThe serum concentration of Regorafenib can be decreased when it is combined with Tocilizumab.Approved
RepaglinideThe serum concentration of Repaglinide can be decreased when it is combined with Tocilizumab.Approved, Investigational
RetapamulinThe serum concentration of Retapamulin can be decreased when it is combined with Tocilizumab.Approved
RifabutinThe serum concentration of Rifabutin can be decreased when it is combined with Tocilizumab.Approved, Investigational
RifampicinThe serum concentration of Rifampicin can be decreased when it is combined with Tocilizumab.Approved
RilpivirineThe serum concentration of Rilpivirine can be decreased when it is combined with Tocilizumab.Approved
RimonabantThe serum concentration of Rimonabant can be decreased when it is combined with Tocilizumab.Approved, Investigational
RindopepimutThe risk or severity of adverse effects can be increased when Tocilizumab is combined with Rindopepimut.Investigational
RiociguatThe serum concentration of Riociguat can be decreased when it is combined with Tocilizumab.Approved
RisperidoneThe serum concentration of Risperidone can be decreased when it is combined with Tocilizumab.Approved, Investigational
RitonavirThe serum concentration of Ritonavir can be decreased when it is combined with Tocilizumab.Approved, Investigational
RituximabThe risk or severity of adverse effects can be increased when Rituximab is combined with Tocilizumab.Approved
RivaroxabanThe serum concentration of Rivaroxaban can be decreased when it is combined with Tocilizumab.Approved
RofecoxibThe serum concentration of Rofecoxib can be decreased when it is combined with Tocilizumab.Approved, Investigational, Withdrawn
RoflumilastRoflumilast may increase the immunosuppressive activities of Tocilizumab.Approved
RolapitantThe serum concentration of Rolapitant can be decreased when it is combined with Tocilizumab.Approved, Investigational
RomidepsinThe serum concentration of Romidepsin can be decreased when it is combined with Tocilizumab.Approved, Investigational
RopiniroleThe serum concentration of Ropinirole can be decreased when it is combined with Tocilizumab.Approved, Investigational
RopivacaineThe serum concentration of Ropivacaine can be decreased when it is combined with Tocilizumab.Approved
RosuvastatinThe serum concentration of Rosuvastatin can be decreased when it is combined with Tocilizumab.Approved
Rotavirus VaccineThe risk or severity of adverse effects can be increased when Tocilizumab is combined with Rotavirus Vaccine.Approved
RotigotineThe serum concentration of Rotigotine can be decreased when it is combined with Tocilizumab.Approved
RoxithromycinThe serum concentration of Roxithromycin can be decreased when it is combined with Tocilizumab.Approved, Investigational, Withdrawn
Rubella virus vaccineThe risk or severity of adverse effects can be increased when Tocilizumab is combined with Rubella virus vaccine.Approved, Investigational
RucaparibThe serum concentration of Rucaparib can be decreased when it is combined with Tocilizumab.Approved, Investigational
RupatadineThe serum concentration of Rupatadine can be decreased when it is combined with Tocilizumab.Approved
RuxolitinibThe serum concentration of Ruxolitinib can be decreased when it is combined with Tocilizumab.Approved
SafinamideThe serum concentration of Safinamide can be decreased when it is combined with Tocilizumab.Approved, Investigational
SalmeterolThe serum concentration of Salmeterol can be decreased when it is combined with Tocilizumab.Approved
Salmonella typhi ty2 vi polysaccharide antigenThe risk or severity of adverse effects can be increased when Tocilizumab is combined with Salmonella typhi ty2 vi polysaccharide antigen.Approved
Salmonella typhi ty21a live antigenThe risk or severity of adverse effects can be increased when Tocilizumab is combined with Salmonella typhi ty21a live antigen.Approved
SaquinavirThe serum concentration of Saquinavir can be decreased when it is combined with Tocilizumab.Approved, Investigational
SaxagliptinThe serum concentration of Saxagliptin can be decreased when it is combined with Tocilizumab.Approved
SelegilineThe serum concentration of Selegiline can be decreased when it is combined with Tocilizumab.Approved, Investigational, Vet Approved
SelexipagThe serum concentration of Selexipag can be decreased when it is combined with Tocilizumab.Approved
SeratrodastThe serum concentration of Seratrodast can be decreased when it is combined with Tocilizumab.Approved
SertindoleThe serum concentration of Sertindole can be decreased when it is combined with Tocilizumab.Approved, Investigational, Withdrawn
SertralineThe serum concentration of Sertraline can be decreased when it is combined with Tocilizumab.Approved
SevofluraneThe serum concentration of Sevoflurane can be decreased when it is combined with Tocilizumab.Approved, Vet Approved
SibutramineThe serum concentration of Sibutramine can be decreased when it is combined with Tocilizumab.Approved, Illicit, Investigational, Withdrawn
SildenafilThe serum concentration of Sildenafil can be decreased when it is combined with Tocilizumab.Approved, Investigational
SilodosinThe serum concentration of Silodosin can be decreased when it is combined with Tocilizumab.Approved
SimvastatinThe serum concentration of Simvastatin can be decreased when it is combined with Tocilizumab.Approved
Sipuleucel-TThe therapeutic efficacy of Sipuleucel-T can be decreased when used in combination with Tocilizumab.Approved, Investigational
SirolimusThe serum concentration of Sirolimus can be decreased when it is combined with Tocilizumab.Approved, Investigational
SitagliptinThe serum concentration of Sitagliptin can be decreased when it is combined with Tocilizumab.Approved, Investigational
SolifenacinThe serum concentration of Solifenacin can be decreased when it is combined with Tocilizumab.Approved
SonidegibThe serum concentration of Sonidegib can be decreased when it is combined with Tocilizumab.Approved, Investigational
SorafenibThe serum concentration of Sorafenib can be decreased when it is combined with Tocilizumab.Approved, Investigational
SpiramycinThe serum concentration of Spiramycin can be decreased when it is combined with Tocilizumab.Approved
SRP 299The risk or severity of adverse effects can be increased when Tocilizumab is combined with SRP 299.Investigational
SufentanilThe serum concentration of Sufentanil can be decreased when it is combined with Tocilizumab.Approved, Investigational
SulfadiazineThe serum concentration of Sulfadiazine can be decreased when it is combined with Tocilizumab.Approved, Investigational, Vet Approved
SulfamethoxazoleThe serum concentration of Sulfamethoxazole can be decreased when it is combined with Tocilizumab.Approved
SulfinpyrazoneThe serum concentration of Sulfinpyrazone can be decreased when it is combined with Tocilizumab.Approved
SunitinibThe serum concentration of Sunitinib can be decreased when it is combined with Tocilizumab.Approved, Investigational
Synthetic Conjugated Estrogens, AThe serum concentration of Synthetic Conjugated Estrogens, A can be decreased when it is combined with Tocilizumab.Approved
Synthetic Conjugated Estrogens, BThe serum concentration of Synthetic Conjugated Estrogens, B can be decreased when it is combined with Tocilizumab.Approved
TacrolimusTacrolimus may increase the immunosuppressive activities of Tocilizumab.Approved, Investigational
TadalafilThe serum concentration of Tadalafil can be decreased when it is combined with Tocilizumab.Approved, Investigational
TamoxifenThe serum concentration of Tamoxifen can be decreased when it is combined with Tocilizumab.Approved
TamsulosinThe serum concentration of Tamsulosin can be decreased when it is combined with Tocilizumab.Approved, Investigational
TasosartanThe serum concentration of Tasosartan can be decreased when it is combined with Tocilizumab.Approved
Taurochenodeoxycholic acidThe serum concentration of Taurochenodeoxycholic acid can be decreased when it is combined with Tocilizumab.Experimental
TecemotideThe risk or severity of adverse effects can be increased when Tocilizumab is combined with Tecemotide.Investigational
TelaprevirThe serum concentration of Telaprevir can be decreased when it is combined with Tocilizumab.Approved, Withdrawn
TelithromycinThe serum concentration of Telithromycin can be decreased when it is combined with Tocilizumab.Approved
TemazepamThe serum concentration of Temazepam can be decreased when it is combined with Tocilizumab.Approved, Investigational
TemsirolimusThe serum concentration of Temsirolimus can be decreased when it is combined with Tocilizumab.Approved
TeniposideThe serum concentration of Teniposide can be decreased when it is combined with Tocilizumab.Approved
TerbinafineThe serum concentration of Terbinafine can be decreased when it is combined with Tocilizumab.Approved, Investigational, Vet Approved
TerfenadineThe serum concentration of Terfenadine can be decreased when it is combined with Tocilizumab.Approved, Withdrawn
TesmilifeneThe serum concentration of Tesmilifene can be decreased when it is combined with Tocilizumab.Investigational
TestosteroneThe serum concentration of Testosterone can be decreased when it is combined with Tocilizumab.Approved, Investigational
Testosterone cypionateThe serum concentration of Testosterone cypionate can be decreased when it is combined with Tocilizumab.Approved
Testosterone enanthateThe serum concentration of Testosterone enanthate can be decreased when it is combined with Tocilizumab.Approved
Testosterone propionateThe serum concentration of Testosterone propionate can be decreased when it is combined with Tocilizumab.Approved, Investigational, Vet Approved, Withdrawn
Testosterone undecanoateThe serum concentration of Testosterone undecanoate can be decreased when it is combined with Tocilizumab.Approved, Investigational
TetracyclineThe serum concentration of Tetracycline can be decreased when it is combined with Tocilizumab.Approved, Vet Approved
TezacaftorThe serum concentration of Tezacaftor can be decreased when it is combined with Tocilizumab.Approved, Investigational
TG4010The risk or severity of adverse effects can be increased when Tocilizumab is combined with TG4010.Investigational
TheophyllineThe serum concentration of Theophylline can be decreased when it is combined with Tocilizumab.Approved
ThiotepaThe serum concentration of Thiotepa can be decreased when it is combined with Tocilizumab.Approved, Investigational
TiagabineThe serum concentration of Tiagabine can be decreased when it is combined with Tocilizumab.Approved, Investigational
TicagrelorThe serum concentration of Ticagrelor can be decreased when it is combined with Tocilizumab.Approved
TiclopidineThe serum concentration of Ticlopidine can be decreased when it is combined with Tocilizumab.Approved
TinidazoleThe serum concentration of Tinidazole can be decreased when it is combined with Tocilizumab.Approved, Investigational
TiotropiumThe serum concentration of Tiotropium can be decreased when it is combined with Tocilizumab.Approved
TipranavirThe serum concentration of Tipranavir can be decreased when it is combined with Tocilizumab.Approved, Investigational
TocofersolanThe serum concentration of Tocofersolan can be decreased when it is combined with Tocilizumab.Approved
TocopherolThe serum concentration of Tocopherol can be decreased when it is combined with Tocilizumab.Approved, Investigational
TofacitinibThe risk or severity of adverse effects can be increased when Tocilizumab is combined with Tofacitinib.Approved, Investigational
TolterodineThe serum concentration of Tolterodine can be decreased when it is combined with Tocilizumab.Approved, Investigational
TolvaptanThe serum concentration of Tolvaptan can be decreased when it is combined with Tocilizumab.Approved
ToremifeneThe serum concentration of Toremifene can be decreased when it is combined with Tocilizumab.Approved, Investigational
TrabectedinThe serum concentration of Trabectedin can be decreased when it is combined with Tocilizumab.Approved, Investigational
TramadolThe serum concentration of Tramadol can be decreased when it is combined with Tocilizumab.Approved, Investigational
TrastuzumabTrastuzumab may increase the neutropenic activities of Tocilizumab.Approved, Investigational
Trastuzumab emtansineThe serum concentration of Trastuzumab emtansine can be decreased when it is combined with Tocilizumab.Approved, Investigational
TrazodoneThe serum concentration of Trazodone can be decreased when it is combined with Tocilizumab.Approved, Investigational
TretinoinThe serum concentration of Tretinoin can be decreased when it is combined with Tocilizumab.Approved, Investigational, Nutraceutical
TriamcinoloneThe serum concentration of Triamcinolone can be decreased when it is combined with Tocilizumab.Approved, Vet Approved
TriazolamThe serum concentration of Triazolam can be decreased when it is combined with Tocilizumab.Approved, Investigational
TrimethadioneThe serum concentration of Trimethadione can be decreased when it is combined with Tocilizumab.Approved
TrimethoprimThe serum concentration of Trimethoprim can be decreased when it is combined with Tocilizumab.Approved, Vet Approved
TrimipramineThe serum concentration of Trimipramine can be decreased when it is combined with Tocilizumab.Approved
TroglitazoneThe serum concentration of Troglitazone can be decreased when it is combined with Tocilizumab.Investigational, Withdrawn
TroleandomycinThe serum concentration of Troleandomycin can be decreased when it is combined with Tocilizumab.Approved
Typhoid VaccineThe risk or severity of adverse effects can be increased when Tocilizumab is combined with Typhoid Vaccine.Approved
UdenafilThe serum concentration of Udenafil can be decreased when it is combined with Tocilizumab.Approved, Investigational
UlipristalThe serum concentration of Ulipristal can be decreased when it is combined with Tocilizumab.Approved
ValbenazineThe serum concentration of Valbenazine can be decreased when it is combined with Tocilizumab.Approved, Investigational
ValdecoxibThe serum concentration of Valdecoxib can be decreased when it is combined with Tocilizumab.Approved, Investigational, Withdrawn
VandetanibThe serum concentration of Vandetanib can be decreased when it is combined with Tocilizumab.Approved
VanoxerineThe serum concentration of Vanoxerine can be decreased when it is combined with Tocilizumab.Investigational
VardenafilThe serum concentration of Vardenafil can be decreased when it is combined with Tocilizumab.Approved
Varicella Zoster Vaccine (Live/Attenuated)The risk or severity of adverse effects can be increased when Tocilizumab is combined with Varicella Zoster Vaccine (Live/Attenuated).Approved
VelpatasvirThe serum concentration of Velpatasvir can be decreased when it is combined with Tocilizumab.Approved, Investigational
VemurafenibThe serum concentration of Vemurafenib can be decreased when it is combined with Tocilizumab.Approved
VenetoclaxThe serum concentration of Venetoclax can be decreased when it is combined with Tocilizumab.Approved, Investigational
VenlafaxineThe serum concentration of Venlafaxine can be decreased when it is combined with Tocilizumab.Approved
VerapamilThe serum concentration of Verapamil can be decreased when it is combined with Tocilizumab.Approved
VicrivirocThe serum concentration of Vicriviroc can be decreased when it is combined with Tocilizumab.Investigational
VilanterolThe serum concentration of Vilanterol can be decreased when it is combined with Tocilizumab.Approved
VilazodoneThe serum concentration of Vilazodone can be decreased when it is combined with Tocilizumab.Approved
VinblastineThe serum concentration of Vinblastine can be decreased when it is combined with Tocilizumab.Approved
VincristineThe serum concentration of Vincristine can be decreased when it is combined with Tocilizumab.Approved, Investigational
VindesineThe serum concentration of Vindesine can be decreased when it is combined with Tocilizumab.Approved, Investigational
VinflunineThe serum concentration of Vinflunine can be decreased when it is combined with Tocilizumab.Approved, Investigational
VinorelbineThe serum concentration of Vinorelbine can be decreased when it is combined with Tocilizumab.Approved, Investigational
VismodegibThe serum concentration of Vismodegib can be decreased when it is combined with Tocilizumab.Approved, Investigational
VoriconazoleThe serum concentration of Voriconazole can be decreased when it is combined with Tocilizumab.Approved, Investigational
VortioxetineThe serum concentration of Vortioxetine can be decreased when it is combined with Tocilizumab.Approved, Investigational
VoxilaprevirThe serum concentration of Voxilaprevir can be decreased when it is combined with Tocilizumab.Approved, Investigational
WarfarinThe serum concentration of Warfarin can be decreased when it is combined with Tocilizumab.Approved
Yellow Fever VaccineThe risk or severity of adverse effects can be increased when Tocilizumab is combined with Yellow Fever Vaccine.Approved, Investigational
YohimbineThe serum concentration of Yohimbine can be decreased when it is combined with Tocilizumab.Approved, Investigational, Vet Approved
ZafirlukastThe serum concentration of Zafirlukast can be decreased when it is combined with Tocilizumab.Approved, Investigational
ZalcitabineThe serum concentration of Zalcitabine can be decreased when it is combined with Tocilizumab.Approved, Investigational
ZaleplonThe serum concentration of Zaleplon can be decreased when it is combined with Tocilizumab.Approved, Illicit, Investigational
ZidovudineThe serum concentration of Zidovudine can be decreased when it is combined with Tocilizumab.Approved
ZileutonThe serum concentration of Zileuton can be decreased when it is combined with Tocilizumab.Approved, Investigational, Withdrawn
ZiprasidoneThe serum concentration of Ziprasidone can be decreased when it is combined with Tocilizumab.Approved
ZolpidemThe serum concentration of Zolpidem can be decreased when it is combined with Tocilizumab.Approved
ZomepiracThe serum concentration of Zomepirac can be decreased when it is combined with Tocilizumab.Withdrawn
ZonisamideThe serum concentration of Zonisamide can be decreased when it is combined with Tocilizumab.Approved, Investigational
ZopicloneThe serum concentration of Zopiclone can be decreased when it is combined with Tocilizumab.Approved
ZotepineThe serum concentration of Zotepine can be decreased when it is combined with Tocilizumab.Approved, Investigational, Withdrawn
Food Interactions
Not Available

References

General References
  1. Mihara M, Nishimoto N, Ohsugi Y: The therapy of autoimmune diseases by anti-interleukin-6 receptor antibody. Expert Opin Biol Ther. 2005 May;5(5):683-90. [PubMed:15934843]
  2. FDA Press Announcements: FDA approves first drug to specifically treat giant cell arteritis [Link]
External Links
KEGG Drug
D02596
PubChem Substance
347910344
ChEMBL
CHEMBL1237022
PharmGKB
PA165292659
RxList
RxList Drug Page
Drugs.com
Drugs.com Drug Page
Wikipedia
Tocilizumab
ATC Codes
L04AC07 — Tocilizumab
AHFS Codes
  • 92:36.00 — Disease-modifying Antirheumatic Agents
FDA label
Download (512 KB)
MSDS
Download (482 KB)

Clinical Trials

Clinical Trials
PhaseStatusPurposeConditionsCount
0WithdrawnTreatmentMultiple Myeloma (MM) / Myeloma-Multiple1
1Active Not RecruitingTreatmentB-Cell Chronic Lymphocytic Leukemia / Chronic Lymphocytic Leukaemia (CLL)1
1Active Not RecruitingTreatmentJuvenile Idiopathic Arthritis (JIA)1
1Active Not RecruitingTreatmentLeukemia Acute Myeloid Leukemia (AML)1
1CompletedBasic ScienceRheumatoid Arthritis1
1CompletedTreatmentCastleman's Disease1
1CompletedTreatmentHealthy Volunteers2
1CompletedTreatmentJuvenile Idiopathic Arthritis (JIA)2
1CompletedTreatmentJuvenile Idiopathic Arthritis (JIA) / Juvenile Idiopathic Arthritis, Rheumatoid Arthritis / Systemic Juvenile Idiopathic Arthritis (SJIA)1
1CompletedTreatmentRheumatoid Arthritis3
1CompletedTreatmentSchizophrenic Disorders1
1RecruitingTreatmentCancer, Breast1
1RecruitingTreatmentFollicular Lymphoma (FL) / Lymphoma, B-Cell / Non-Hodgkin's Lymphoma (NHL)1
1RecruitingTreatmentNon-Hodgkin's Lymphoma (NHL)1
1RecruitingTreatmentPharmacokinetics1
1RecruitingTreatmentPsychotic Disorder NOS / Schizophrenic Disorders1
1, 2Active Not RecruitingBasic ScienceHuman Immunodeficiency Virus (HIV) Infections1
1, 2Active Not RecruitingTreatmentNeuromyelitis Optica / Neuromyelitis Optica Spectrum Disorders1
1, 2Active Not RecruitingTreatmentDiffuse posterior uveitis / Non-infectious Intermediate, Posterior, or Pan-uveitis / Pan-uveitis / Uveitis, Intermediate1
1, 2CompletedTreatmentEnd Stage Renal Disease (ESRD)1
1, 2CompletedTreatmentRecurrent Ovarian Cancer1
1, 2Not Yet RecruitingTreatmentHepatocellular,Carcinoma1
1, 2RecruitingPreventionCytokine Release Syndrome / Stem Cell Transplant Complications1
1, 2RecruitingTreatmentAcute Lymphocytic Leukemia, Pediatric / B-cell Acute Lymphoblastic Leukemia1
1, 2RecruitingTreatmentChronic Subdural Hematomas1
1, 2TerminatedTreatmentAcute Graft Versus Host Disease1
1, 2TerminatedTreatmentJuvenile Idiopathic Arthritis Associated Uveitis1
2Active Not RecruitingPreventionAcute Graft Versus Host Disease After Allogeneic Hematopoietic Stem Cell Transplantation / Hematopoietic Stem Cell Transplantation (HSCT)1
2Active Not RecruitingTreatmentAmyotrophic Lateral Sclerosis (ALS) / Lou Gehrig's Disease / Motor Neurone Disease1
2CompletedTreatmentGiant Cells Arteritis2
2CompletedTreatmentNon-ST Elevation Myocardial Infarction1
2CompletedTreatmentPolymyalgia Rheumatica (PMR)1
2CompletedTreatmentPulmonary Arterial Hypertension (PAH)1
2CompletedTreatmentRheumatoid Arthritis5
2Not Yet RecruitingTreatmentDiabetic Macular Edema (DME)1
2RecruitingTreatmentAcute Lymphoblastic Leukaemias (ALL) / Leukaemia, Acute / Leukemia Acute Myeloid Leukemia (AML) / Leukemias / Lymphoma, Hodgkins / Myelodysplastic Syndromes / Myelodysplastic-Myeloproliferative Diseases / Myeloproliferative Disorders / Non Hodgkin Lymphoma (NHL)1
2RecruitingTreatmentBehcet's Syndrome / Uveitis1
2RecruitingTreatmentBiotherapy / Uveitis1
2RecruitingTreatmentCastleman's Disease / Giant Lymph Node Hyperplasia1
2RecruitingTreatmentCoronary Heart Disease (CHD) / Myocardial Infarction1
2RecruitingTreatmentDermatomyositis / Polymyositis1
2RecruitingTreatmentDiabetes, Diabetes Mellitus Type 1 / New-onset Type 1 Diabetes Mellitus / T1D / T1DM1
2RecruitingTreatmentFamilial Mediterranean Fever (FMF )1
2RecruitingTreatmentLate Complication From Kidney Transplant1
2RecruitingTreatmentLeukemias1
2RecruitingTreatmentLymphohistiocytosis, Hemophagocytic1
2RecruitingTreatmentMajor Depressive Disorder (MDD)1
2RecruitingTreatmentSchnitzler's Syndrome1
2RecruitingTreatmentUnresectable Pancreatic Carcinoma1
2TerminatedTreatmentBehcet's Syndrome1
2TerminatedTreatmentErdheim-Chester Disease (ECD)1
2TerminatedTreatmentGlucocorticosteroid Refractory Acute GVHD1
2TerminatedTreatmentRheumatoid Arthritis1
2Unknown StatusTreatmentAdult's Still Disease1
2Unknown StatusTreatmentFibrous Dysplasia of Bone1
2WithdrawnSupportive CareGraft Versus Host Disease (GVHD)1
2WithdrawnTreatmentRelapsing Polychondritis1
2, 3RecruitingTreatmentNeuromyelitis Optica / Neuromyelitis Optica Spectrum Disorders1
2, 3RecruitingTreatmentPrimary Sjögren's Syndrome (pSS)1
3Active Not RecruitingTreatmentGiant Cells Arteritis1
3Active Not RecruitingTreatmentSclerosis, Progressive Systemic1
3CompletedTreatmentGraves´ Ophthalmopathy / Thyroid Associated Ophthalmopathy / Thyroid Eye Disease1
3CompletedTreatmentJuvenile Idiopathic Arthritis (JIA)5
3CompletedTreatmentPolyarticular Juvenile Idiopathic Arthritis1
3CompletedTreatmentRheumatoid Arthritis67
3CompletedTreatmentSclerosis, Progressive Systemic1
3CompletedTreatmentSystemic Juvenile Idiopathic Arthritis (SJIA)3
3RecruitingSupportive CarePolymyalgia Rheumatica1
3RecruitingTreatmentGiant Cells Arteritis1
3RecruitingTreatmentHands Osteoarthritis1
3RecruitingTreatmentJuvenile Idiopathic Arthritis (JIA)1
3RecruitingTreatmentPolymyalgia Rheumatica1
3RecruitingTreatmentRheumatoid Arthritis2
3RecruitingTreatmentTakayasu's Disease1
3TerminatedTreatmentAnkylosing Spondylitis (AS)2
3TerminatedTreatmentJuvenile Idiopathic Arthritis (JIA)1
3TerminatedTreatmentRheumatoid Arthritis1
4Active Not RecruitingTreatmentRheumatoid Arthritis2
4CompletedNot AvailableHealthy Volunteers1
4CompletedHealth Services ResearchRheumatoid Arthritis1
4CompletedOtherRheumatoid Arthritis1
4CompletedTreatmentCardiovascular Disease, Rheumatoid Arthritis / Rheumatoid Arthritis1
4CompletedTreatmentRheumatoid Arthritis15
4CompletedTreatmentSchizoaffective Disorders / Schizophrenic Disorders1
4Enrolling by InvitationTreatmentRheumatoid Arthritis1
4RecruitingBasic ScienceRheumatoid Arthritis1
4RecruitingTreatmentGiant Cells Arteritis1
4RecruitingTreatmentJuvenile Idiopathic Arthritis (JIA)2
4RecruitingTreatmentRheumatoid Arthritis5
4TerminatedTreatmentRheumatoid Arthritis3
4WithdrawnTreatmentRheumatoid Arthritis1
Not AvailableActive Not RecruitingNot AvailableRheumatoid Arthritis3
Not AvailableCompletedNot AvailablePolymyalgia Rheumatica1
Not AvailableCompletedNot AvailablePsoriatic Arthritis / Rheumatoid Arthritis / Spondyloarthritis1
Not AvailableCompletedNot AvailableRheumatoid Arthritis13
Not AvailableCompletedPreventionBMI >30 kg/m2 / Type 2 Diabetes Mellitus1
Not AvailableCompletedTreatmentMyocardial Infarction1
Not AvailableCompletedTreatmentRelapsing Polychondritis1
Not AvailableCompletedTreatmentRheumatoid Arthritis3
Not AvailableNo Longer AvailableNot AvailableJuvenile Idiopathic Arthritis (JIA)1
Not AvailableNot Yet RecruitingNot AvailableRheumatoid Arthritis1
Not AvailableRecruitingNot AvailableAnkylosing Spondylitis (AS) / Psoriatic Arthritis / Rheumatoid Arthritis1
Not AvailableRecruitingNot AvailableInflammatory Reaction / Rheumatoid Arthritis1
Not AvailableRecruitingNot AvailableRheumatoid Arthritis5
Not AvailableRecruitingOtherAdiposity1
Not AvailableRecruitingTreatmentLymphoblastic Leukemia, Acute, Childhood1
Not AvailableTerminatedTreatmentRheumatoid Arthritis, Juvenile / Still's Disease, Juvenile Onset1

Pharmacoeconomics

Manufacturers
Not Available
Packagers
Not Available
Dosage forms
FormRouteStrength
Injection, solutionSubcutaneous180 mg/mL
Injection, solution, concentrateIntravenous20 mg/mL
SolutionIntravenous200 mg
SolutionIntravenous400 mg
SolutionIntravenous80 mg
SolutionSubcutaneous162 mg
Prices
Not Available
Patents
Patent NumberPediatric ExtensionApprovedExpires (estimated)
CA2201781No2010-01-122015-06-07Canada
CA1341152No2000-12-122017-12-12Canada

Properties

State
Liquid
Experimental Properties
Not Available

Taxonomy

Description
Not Available
Kingdom
Organic Compounds
Super Class
Organic Acids
Class
Carboxylic Acids and Derivatives
Sub Class
Amino Acids, Peptides, and Analogues
Direct Parent
Peptides
Alternative Parents
Not Available
Substituents
Not Available
Molecular Framework
Not Available
External Descriptors
Not Available

Targets

Kind
Protein
Organism
Human
Pharmacological action
Yes
Actions
Antibody
General Function
Protein homodimerization activity
Specific Function
Part of the receptor for interleukin 6. Binds to IL6 with low affinity, but does not transduce a signal. Signal activation necessitate an association with IL6ST. Activation may lead to the regulati...
Gene Name
IL6R
Uniprot ID
P08887
Uniprot Name
Interleukin-6 receptor subunit alpha
Molecular Weight
51547.015 Da
References
  1. Smolen JS, Maini RN: Interleukin-6: a new therapeutic target. Arthritis Res Ther. 2006;8 Suppl 2:S5. Epub 2006 Jul 28. [PubMed:16899109]

Drug created on March 19, 2008 10:20 / Updated on July 13, 2018 01:10